ABSTRACT
IL-17 is one of more than 30 kinds of interleukin, which plays an important role in many biological processes. Under normal circumstances, IL-17 can cause inflammation. However, under pathological conditions, IL-17 can also promote a variety of tumors. Hepatocellular carcinoma (HCC) is the most common type of liver cancer.It has rapid development, poor prognosis, easy metastasis, and obvious inflammatory reaction in tumor microenvironment. These biological characteristics suggest that the occurrence and development of HCC are related to the expression of IL-17. IL-17 can affect the growth, development and autophagy of hepatocellular carcinoma through a variety of ways. For example, promot the growth of hepatocellular carcinoma through the AKT/IL-6/JAK2/STAT3 signaling pathway and the miR-383/STAT3 axis, increase the expression of MMPs by activating the NF-κB signaling pathway to promote hepatocellular carcinoma metastasis, enhance the expression of PIAS1 through the NF-κB pathway to inhibit the anti-tumor effect of IFN-γ, and by inhibiting the degradation of Bcl2 in Bcl2-Beclin1 to inhibit autophagy of hepatocellular carcinoma cells. This article reviews the research status of IL-17 in the pathogenesis of hepatocellular carcinoma.